Ernst & Young's Buck Luce named HBA Woman of the Year

Share this article:
Ernst & Young's Buck Luce named HBA Woman of the Year
Ernst & Young's Buck Luce named HBA Woman of the Year
The Healthcare Businesswomen's Association named Ernst & Young global pharma lead Carolyn Buck Luce, calling her “a dedicated leader promoting women's advancement in healthcare.”

Buck Luce has spent 21 years at Ernst & Young, where she is global pharmaceutical leader, responsible for overseeing strategy, thought leadership, resourceing, learning and solutions for the firm's life sciences clients. Before that spent seventeen years in banking, consulting and government. In her current role she has championed an industry-wide conversation about “Pharma 3.0” based on the firm's strategic insights. She is the co-founder of the Corporate Council for the White House Project, which brings together major orporations to enhance the perception of women as business leaders, and co-chair and co-founder of The Talent Innovation Task Force. She also serves on the Mayor's Commission on Women's Issues and has served as chair of the Board of Directors of the New York Women's Foundation.

“Carolyn exemplifies the remarkable reach and unmistakable impact of inclusive leadership,” said Jim Turley, chairman and CEO of Ernst & Young. “She has driven Ernst & Young's work in the global life sciences market during a period characterized by complexity, increasing regulation and a constant demand for innovation, yet her ability to connect people and solutions leaves a lasting mark on both the health care and professional services industries. At the same time, Carolyn accelerated her efforts to champion the advancement of women leaders through thought leadership and community service.”

"It is a true privilege to be recognized by the Healthcare Businesswomen's Association with this award," said Ms. Buck Luce. "Today's healthcare industry presents huge opportunities and challenges that will require all of our best talent focusing on improving health outcomes for individual patients and societies. The discovery, development and life cycle management of diverse global talent will be the key driver of innovation in the future. I look forward to continuing to work closely with the HBA in finding ways to accelerate the enormous potential of professional women throughout the healthcare ecosystem."

She will be honored at HBA's 23rd Annual Woman of the Year event Thursday, May 3 at the Hilton New York.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...